Cargando…
Large-scale pharmacological profiling of 3D tumor models of cancer cells
The discovery of chemotherapeutic agents for the treatment of cancer commonly uses cell proliferation assays in which cells grow as two-dimensional (2D) monolayers. Compounds identified using 2D monolayer assays often fail to advance during clinical development, most likely because these assays do n...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261027/ https://www.ncbi.nlm.nih.gov/pubmed/27906188 http://dx.doi.org/10.1038/cddis.2016.360 |
_version_ | 1782499505675960320 |
---|---|
author | Mathews Griner, Lesley A Zhang, Xiaohu Guha, Rajarshi McKnight, Crystal Goldlust, Ian S Lal-Nag, Madhu Wilson, Kelli Michael, Sam Titus, Steve Shinn, Paul Thomas, Craig J Ferrer, Marc |
author_facet | Mathews Griner, Lesley A Zhang, Xiaohu Guha, Rajarshi McKnight, Crystal Goldlust, Ian S Lal-Nag, Madhu Wilson, Kelli Michael, Sam Titus, Steve Shinn, Paul Thomas, Craig J Ferrer, Marc |
author_sort | Mathews Griner, Lesley A |
collection | PubMed |
description | The discovery of chemotherapeutic agents for the treatment of cancer commonly uses cell proliferation assays in which cells grow as two-dimensional (2D) monolayers. Compounds identified using 2D monolayer assays often fail to advance during clinical development, most likely because these assays do not reproduce the cellular complexity of tumors and their microenvironment in vivo. The use of three-dimensional (3D) cellular systems have been explored as enabling more predictive in vitro tumor models for drug discovery. To date, small-scale screens have demonstrated that pharmacological responses tend to differ between 2D and 3D cancer cell growth models. However, the limited scope of screens using 3D models has not provided a clear delineation of the cellular pathways and processes that differentially regulate cell survival and death in the different in vitro tumor models. Here we sought to further understand the differences in pharmacological responses between cancer tumor cells grown in different conditions by profiling a large collection of 1912 chemotherapeutic agents. We compared pharmacological responses obtained from cells cultured in traditional 2D monolayer conditions with those responses obtained from cells forming spheres versus cells already in 3D spheres. The target annotation of the compound library screened enabled the identification of those key cellular pathways and processes that when modulated by drugs induced cell death in all growth conditions or selectively in the different cell growth models. In addition, we also show that many of the compounds targeting these key cellular functions can be combined to produce synergistic cytotoxic effects, which in many cases differ in the magnitude of their synergism depending on the cellular model and cell type. The results from this work provide a high-throughput screening framework to profile the responses of drugs both as single agents and in pairwise combinations in 3D sphere models of cancer cells. |
format | Online Article Text |
id | pubmed-5261027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-52610272017-01-26 Large-scale pharmacological profiling of 3D tumor models of cancer cells Mathews Griner, Lesley A Zhang, Xiaohu Guha, Rajarshi McKnight, Crystal Goldlust, Ian S Lal-Nag, Madhu Wilson, Kelli Michael, Sam Titus, Steve Shinn, Paul Thomas, Craig J Ferrer, Marc Cell Death Dis Original Article The discovery of chemotherapeutic agents for the treatment of cancer commonly uses cell proliferation assays in which cells grow as two-dimensional (2D) monolayers. Compounds identified using 2D monolayer assays often fail to advance during clinical development, most likely because these assays do not reproduce the cellular complexity of tumors and their microenvironment in vivo. The use of three-dimensional (3D) cellular systems have been explored as enabling more predictive in vitro tumor models for drug discovery. To date, small-scale screens have demonstrated that pharmacological responses tend to differ between 2D and 3D cancer cell growth models. However, the limited scope of screens using 3D models has not provided a clear delineation of the cellular pathways and processes that differentially regulate cell survival and death in the different in vitro tumor models. Here we sought to further understand the differences in pharmacological responses between cancer tumor cells grown in different conditions by profiling a large collection of 1912 chemotherapeutic agents. We compared pharmacological responses obtained from cells cultured in traditional 2D monolayer conditions with those responses obtained from cells forming spheres versus cells already in 3D spheres. The target annotation of the compound library screened enabled the identification of those key cellular pathways and processes that when modulated by drugs induced cell death in all growth conditions or selectively in the different cell growth models. In addition, we also show that many of the compounds targeting these key cellular functions can be combined to produce synergistic cytotoxic effects, which in many cases differ in the magnitude of their synergism depending on the cellular model and cell type. The results from this work provide a high-throughput screening framework to profile the responses of drugs both as single agents and in pairwise combinations in 3D sphere models of cancer cells. Nature Publishing Group 2016-12 2016-12-01 /pmc/articles/PMC5261027/ /pubmed/27906188 http://dx.doi.org/10.1038/cddis.2016.360 Text en Copyright © 2016 The Author(s) http://creativecommons.org/licenses/by/4.0/ Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Article Mathews Griner, Lesley A Zhang, Xiaohu Guha, Rajarshi McKnight, Crystal Goldlust, Ian S Lal-Nag, Madhu Wilson, Kelli Michael, Sam Titus, Steve Shinn, Paul Thomas, Craig J Ferrer, Marc Large-scale pharmacological profiling of 3D tumor models of cancer cells |
title | Large-scale pharmacological profiling of 3D tumor models of cancer cells |
title_full | Large-scale pharmacological profiling of 3D tumor models of cancer cells |
title_fullStr | Large-scale pharmacological profiling of 3D tumor models of cancer cells |
title_full_unstemmed | Large-scale pharmacological profiling of 3D tumor models of cancer cells |
title_short | Large-scale pharmacological profiling of 3D tumor models of cancer cells |
title_sort | large-scale pharmacological profiling of 3d tumor models of cancer cells |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261027/ https://www.ncbi.nlm.nih.gov/pubmed/27906188 http://dx.doi.org/10.1038/cddis.2016.360 |
work_keys_str_mv | AT mathewsgrinerlesleya largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT zhangxiaohu largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT guharajarshi largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT mcknightcrystal largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT goldlustians largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT lalnagmadhu largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT wilsonkelli largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT michaelsam largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT titussteve largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT shinnpaul largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT thomascraigj largescalepharmacologicalprofilingof3dtumormodelsofcancercells AT ferrermarc largescalepharmacologicalprofilingof3dtumormodelsofcancercells |